Herceptin Biosimilars Market to Reach USD 10.4 Billion by 2036 as Trastuzumab Biosimilars Dominate Demand
核心洞察
The global Herceptin biosimilars market is projected to grow from USD 4.3 billion in 2026 to USD 10.4 billion by 2036, at a 9.2% CAGR.
Trastuzumab biosimilars are forecast to hold 82.0% of product demand in 2026, with hospital pharmacies leading distribution at a 54.0% share.
HER2-positive breast cancer (搜索) is expected to represent 64.0% of indications in 2026, while intravenous administration leads the route category at 78.0%.
The global Herceptin biosimilars market is forecast to expand from USD 4.3 billion in 2026 to USD 10.4 billion by 2036, reflecting a compound annual growth rate (CAGR) of 9.2% over the forecast period, according to Future Market Insights. This growth is driven by hospital oncology systems converting regulatory comparability into recurring demand through formulary control, infusion capacity, and pharmacy oversight, as healthcare providers seek lower-cost treatment options within oncology formularies.
The World Health Organization reported in February 2025 that trastuzumab biosimilars cost 65% less than reference therapy, a pricing advantage that has accelerated adoption across developed and emerging healthcare systems. However, the report emphasizes that access requires dependable supply, underscoring the operational challenges facing manufacturers and hospital contracting teams.
Market Segmentation and Demand Drivers
Trastuzumab biosimilars are projected to hold 82.0% of product demand in 2026, driven by established regulatory approvals and broad adoption across approved oncology indications. Approved trastuzumab biosimilars enter established HER2 (搜索)-positive breast and gastric cancer protocols against the same reference medicine, with hospital committees comparing regulatory evidence, vial presentation, and supply terms during formulary review.
Hospital pharmacies are estimated to account for 54.0% of distribution in 2026, as they oversee the storage and traceability requirements of biologic cancer therapies. Hospital pharmacies turn an intravenous biologic into a scheduled treatment dose under controlled oncology protocols, managing cold storage plus patient-specific preparation and release to infusion units.
By indication, HER2-positive breast cancer (搜索) is forecast to represent 64.0% of indications in 2026, supported by its large patient population and the widespread use of trastuzumab-based treatment regimens. The International Agency for Research on Cancer reported in October 2024 that more than 2.3 million new breast cancer cases occurred worldwide during 2022. HER2-positive gastric cancer (搜索) forms a second approved indication with different testing and treatment routes.
Intravenous administration is forecast to lead the route category at 78.0% share in 2026, due to established hospital infusion workflows. Commercial trastuzumab biosimilars remain concentrated in intravenous presentations that fit established injectable drug platforms.
Regulatory Landscape and Approval Routes
Approval routes determine which products hospitals can contract. The FDA's June 2026 Purple Book lists six licensed trastuzumab biosimilars. Japan and the United Kingdom use national routes, while France and Germany rely on reimbursement lists and tenders, which shape launch timing for monoclonal antibody therapies and formulary conversion.
In February 2026, Celltrion completed the pivotal Herzuma SC regulatory trial and planned submissions in Europe and Korea. The program reported equivalent pharmacokinetics with administration lasting about five minutes for scheduled hospital use. In January 2026, Accord BioPharma reported HERCESSI preferred status on Express Scripts national commercial formularies, making HERCESSI one of two preferred trastuzumab biosimilars under that national commercial coverage. In November 2025, Sandoz signed a global license agreement with EirGenix for the pertuzumab biosimilar EG1206A, with EirGenix retaining development and manufacturing while Sandoz received commercialization rights outside specified Asian markets.
Regional Outlook
Country-level CAGRs span 1.1 percentage points between Japan and Germany across mature oncology systems. Japan is projected to expand at a 9.3% CAGR through 2036, reflecting continued policy support for biosimilar adoption within the national reimbursement system, with a March 2026 MHLW notice covering four trastuzumab biosimilar presentations. The United Kingdom is anticipated to advance at a 9.1% CAGR, supported by NHS England's April 2025 best-value biological medicines framework. The United States is expected to record an 8.8% CAGR, aided by broad reimbursement access for physician-administered biologics. France is forecast to expand at an 8.5% CAGR, with uptake closely tied to hospital reimbursement structures, while Germany is estimated to post an 8.2% CAGR, shaped by competitive tendering and structured procurement practices.
Competitive Landscape
Celltrion, Samsung Bioepis (搜索), Amgen, Pfizer, Biocon Biologics (搜索), Sandoz, Organon, Teva, Dr. Reddy's Laboratories, and Shanghai Henlius form the notable companies in the industry. The competitive outlook combines biosimilar developers with multinational commercialization platforms and regional oncology manufacturers, while hospital tenders favor comparative evidence plus dependable production and clear market rights.
Anurag Sharma, Principal Consultant for Healthcare at Future Market Insights, offered perspective on the commercial dynamics: "Hospital contracting teams should compare delivered treatment cost with vial use, supply resilience and the work required to change pharmacy protocols. Commercial value depends on keeping trastuzumab available across scheduled cycles instead of winning an unsustainable tender."
Challenges and Opportunities
Tender discounting weakens returns because validated production, pharmacovigilance, and reserve inventory remain necessary during contracted supply. Tender discounting reduces net revenue although biologics contract manufacturing still requires validated production and pharmacovigilance, with manufacturers carrying traceability and reserve-inventory duties.
Subcutaneous delivery represents a key opportunity, giving developers a route beyond vial discounting and infusion-chair competition. However, each formulation requires comparative evidence with compatible hospital monitoring, and revenue depends on dependable device supply and implementation support during commercial rollout across infusion centers.